← Eichor
Condition: High Risk Non Muscle Invasive Bladder Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: High Risk Non Muscle Invasive Bladder Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NA · 8 location(s) · Tianjin Medical University Second Hospital · NCT07180212Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2 · 3 location(s) · Tianjin Medical University Second Hospital · NCT07475403To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients Wi
Phase 1/Phase 2 · 6 location(s) · RemeGen Co., Ltd. · NCT06378242A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Pati
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07036731Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder
Phase 2 · 71 location(s) · Protara Therapeutics · NCT05951179Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Inte
Phase 3 · 1 location(s) · Fujian Medical University Union Hospital · NCT06441110Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladde
Phase 2 · 1 location(s) · Shanxi Province Cancer Hospital · NCT07646145Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
Phase 1 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06551233A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Phase 1/Phase 2 · 20 location(s) · SURGE Therapeutics · NCT05710848A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT05410730The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non
Phase N/A · 2 location(s) · Tianjin Medical University Second Hospital · NCT07130578Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIB
Phase 3 · 3 location(s) · Shaogang Wang · NCT06696794Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
Phase 2 · 1 location(s) · Changhai Hospital · NCT07307456A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Phase 2 · 89 location(s) · Merck Sharp & Dohme LLC · NCT06833073A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasiv
Phase 3 · 110 location(s) · Janssen Research & Development, LLC · NCT06919965A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle
Phase 1 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06108492A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Phase 2 · 2 location(s) · ImmVira Pharma Co. Ltd · NCT06971614Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Gue
Phase 2 · 14 location(s) · Lepu Biopharma Co., Ltd. · NCT07283835Predicting BCG Response
Phase N/A · 6 location(s) · Cedars-Sinai Medical Center · NCT04564781Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours
Phase 4 · 1 location(s) · University of Roma La Sapienza · NCT05962541Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05123625DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Phase 3 · 1 location(s) · Fudan University · NCT07207824Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Phase 1/Phase 2 · 6 location(s) · Zhuhai Beihai Biotech Co., Ltd · NCT06732531Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2 · 65 location(s) · CG Oncology, Inc. · NCT06567743Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC
Phase 2 · 1 location(s) · Relmada Therapeutics, Inc. · NCT06663137Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive B
Phase 3 · 6 location(s) · Verity Pharmaceuticals Inc. · NCT05037279Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Phase N/A · 2 location(s) · University of Texas Southwestern Medical Center · NCT05825950A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Mi
Phase N/A · 1 location(s) · Peking University First Hospital · NCT06991868LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Phase 1/Phase 2 · 102 location(s) · enGene, Inc. · NCT04752722Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Partici
Phase 3 · 6 location(s) · Protara Therapeutics · NCT07480356
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.